FDA Approval Insights: Olaparib/Bevacizumab in Advanced Ovarian Cancer
Season 3, Episode 3, May 14, 2020, 05:43 PM
In our exclusive interview, Dr. Herzog discusses the FDA approval of the combination of olaparib and bevacizumab as frontline maintenance therapy for patients with advanced ovarian cancer, the safety profile of the combination, and the clinical implications of the approval.